Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery.

PURPOSE: To establish the safety of an intracameral injection of self-preserved moxifloxacin at the conclusion of routine cataract surgery for the prophylaxis of endophthalmitis and to assess the effect on macular thickness using optical coherence tomography (OCT).

SETTING: Private practice, Bettendorf, Iowa, USA.

METHODS: A retrospective review of the charts of consecutive cataract procedures was conducted to compare outcome measures in patients with or without intracameral injection of moxifloxacin that was diluted to a 0.1% solution in a 100 microg/0.1 mL dose at the conclusion of cataract surgery. In addition, in a prospective manner, macular thickness was measured by OCT in 31 eyes before and 6 weeks after cataract surgery in patients who received the intracameral injection.

RESULTS: Aqueous cell counts 1 day postoperatively were significantly lower in the moxifloxacin-treated group (P=.0007). At 1 week, there was no difference between the 2 treatment groups in the number of patients who had no or trace cells. No stromal edema was observed in the moxifloxacin-treated group. Optical coherence tomography studies showed mean increases of less than 3% in macular thickness in all sectors and less than 4% in macular volume at all locations. No drug-related adverse effects were reported.

CONCLUSION: No untoward effects were observed after intracameral injection of moxifloxacin 0.5% ophthalmic solution diluted to a 0.1% concentration at the conclusion of routine cataract surgery.